ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsPrimary biliary cholangitis (PBC) is an autoimmune liver disease whose effect on long-term survival remains unclear. We aimed to compare the prognosis of patients with biopsy-confirmed PBC with population comparators.
methodsWe used nationwide healthcare registries to include all Danish patients diagnosed with histologically confirmed PBC in 1998-2020. We estimated the prevalence of PBC and the incidence in 2016-2019. Dividing PBC by presence or absence of cirrhosis, we used the cumulative incidence function to estimate the risk of death and HCC. We included 5:1 age- and sex-matched population comparators.
resultsWe included 1163 PBC patients (88.1% women, median age at diagnosis = 59.7 years); those with cirrhosis were older (median 63.9 vs. 59.0). Patients had more comorbidity at diagnosis than comparators, especially connective tissue disease. On January 1st 2021, the prevalence of PBC was 22.3 per 100,000 population. The incidence rate in 2016-2019 was 2.80 (95% CI: 2.58-3.02) per 100,000 population per year. PBC patients with cirrhosis had a higher 10-year risk of death than their matched comparators, adjusted relative risk = 2.41 (95% CI: 1.89-3.09). For patients with non-cirrhotic PBC, the 10-year risk of death was 18.5% (95% CI: 15.5-21.7) versus 14.3% (95% CI: 13.0-15.6) for their comparators, adjusted relative risk = 1.22 (95% CI: 1.03-1.47). Patients with cirrhotic PBC had a 10-year risk of HCC at 2.6% (95% CI: 0.8-6.0).
conclusionsPatients with PBC have a worse prognosis than the general population irrespective of the presence or absence of cirrhosis at the time of PBC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.